Johnson & Johnson's COVID shot could return by late this week with some extra safety warnings: Fauci CVS, Walgreens begin rolling out over-the-counter COVID tests from Abbott, Ellume and more White House to give CDC $1.7B to help find and track COVID-19 variants With the competition struggling, Pfizer's COVID vaccine sales could hit $24B this year: analyst FDA orders shutdown at Emergent's troubled plant 2 weeks after handing J&J the keys Adagio raises a monster $336M round for bespoke COVID-19 drug battle A look at how Blues plans are aiming to get their members vaccinated Serum Institute nears $400M grant to boost AstraZeneca COVID shot production—just as material shortages mount As variants take hold, FDA revokes authorization of Eli Lilly's solo COVID-19 antibody Tonix hopes for COVID-19 drug tonic as it pens OyaGen antiviral pact COVID-19 tracker: CVS, Walgreens offer at-home tests; Sputnik V highly effective in new study, developers say Featured Story | By Fraiser Kansteiner The U.S. will likely bring Johnson & Johnson's COVID-19 vaccine back into its immunization scheme, alongside some new restrictions or safety warnings, NIAID director Anthony Fauci said. The country should know by Friday when it can expect to see the single-dose vaccine back on the menu. read more |
| |
|---|
|
Top Stories By Conor Hale After spending months churning out tens of millions of its card-sized coronavirus antigen tests, Abbott has begun shipping the BinaxNOW tests nationwide to CVS, Walgreens and Walmart stores. read more By Robert King The White House announced a new investment of $1.7 billion to help the CDC track down the spread of more transmissible variants of COVID-19. read more By Kevin Dunleavy With the COVID-19 vaccine landscape shifting in favor of mRNA shots, Bernstein analyst Ronny Gal predicts $24 billion in sales for Pfizer and $14 billion for Moderna this year. The prediction comes amid setbacks for the Johnson & Johnson and AstraZeneca vaccines on both sides of the Atlantic. read more By Kevin Dunleavy Johnson & Johnson’s takeover of COVID-19 vaccine manufacturing at an error-prone Emergent BioSolutions plant didn’t last long. At the FDA's request, Emergent stopped production just two weeks after J&J took over manufacturing its shot there. read more By Ben Adams Adagio Therapeutics has nabbed a massive $336 million series C from a who’s who of investors as it more than triples its previous funding drive last year. read more By Paige Minemyer As a number of states open vaccine eligibility to more adults, Blues insurers across the country are aiming to be a community resource to ensure shots are administered. read more By Fraiser Kansteiner Serum Institute of India is close to winning a $400 million grant from the government to boost production of AstraZeneca's COVID-19 vaccine, The Economic Times reports. The news comes as the company continues to face supply shortfalls, thanks to export controls imposed in the U.S. read more By Noah Higgins-Dunn The FDA has revoked its emergency authorization for Eli Lilly's solo COVID-19 antibody treatment, bamlanivimab, because the drug's benefits no longer outweigh its risks against emerging coronavirus variants. Lilly had called for the med's authorization to be pulled. read more By Ben Adams Tonix Pharmaceuticals is opening an early-stage antiviral asset deal with OyaGen as the pair targets COVID-19. read more By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky CVS and Walgreens are rolling out at-home rapid tests that can be purchased without a prescription. Israel said it inked a new vaccine supply deal with Pfizer and BioNTech. The vaccine developers behind Russia's Sputnik V said a new study found the shot to be 97.6% effective against COVID-19. And more headlines. read more |
